BRIEF

on I-CERAM (EPA:ALICR)

I.Ceram in Judicial Reorganization to Safeguard its Future

Stock price chart of I-CERAM (EPA:ALICR) showing fluctuations.

On April 24, 2024, the Limoges commercial court approved the placing of the company I.Ceram, a manufacturer of innovative biocompatible ceramic implants, into receivership. This decision, following a request from the company itself, aims to protect the interests of its employees and its technologies, while allowing the continuation of its operations. The observation period is set at six months.

I.Ceram, known for its innovations in the medical field, notably implants loaded with antibiotics intended to treat bone infections, faces difficulties linked to regulatory changes and financing. Despite notable clinical advances and several awards, challenges remain, leading to the need for this legal protection.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all I-CERAM news